Contribution: Industrial Research Assistance Program – Contributions to Firms
Simini Technologies Inc.
$34,263.60
Atopic Dermatitis Study in Dogs
FY 2018-19 · 2018-10-17
Summary
SMN-023 is new a topical therapy for canine atopic dermatitis. This study is designed to show proof of concept that SMN-023 can be the first pharmaceutical approved as a maintenance therapy to delay the onset of atopic dermatitis flares in dogs.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Whitby|Whitby, Ontario, Canada
Recipient Type
For-profit organization
Business Number
719672123
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2018-10-17 | 2018-19 | $82,565.00 |
| 1 | 2018-10-17 | 2018-19 | $34,263.60 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is -48,301.4 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de - 48 301 dollars.
Agreement End Date
2019-11-30
Agreement Number
914972
Agreement Start Date
2018-10-17
Agreement Title
Atopic Dermatitis Study in Dogs
Agreement Title (French)
Étude sur la dermite atopique chez le chien
Agreement Type
Contribution
Agreement Value
$34,263.60
Amendment Date
2019-09-03
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
SMN-023 is new a topical therapy for canine atopic dermatitis. This study is designed to show proof of concept that SMN-023 can be the first pharmaceutical approved as a maintenance therapy to delay the onset of atopic dermatitis flares in dogs.
Description (French)
SMN-023 est un nouveau traitement topique de la dermite atopique canine. Cette étude est conçue pour démontrer le principe selon lequel SMN-023 peut être le premier médicament approuvé en tant que traitement d'entretien pour retarder l'apparition des poussées de dermite atopique chez le chien.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Whitby
Federal Riding (French)
Whitby
Federal Riding Number
35114
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
719672123
Recipient City
Whitby|Whitby
Recipient Country
CA
Recipient Legal Name
Simini Technologies Inc.
Recipient Postal Code
L1R 1V8
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2018-2019-Q3-914972
